Associations between CD133, CK19 and G2/M in cirrhotic HCV (genotype-4) patients with or without accompanying tumor

El-Emshaty, Hoda; Saad, Entsar A.; Gouida, Mona S.; Elshahawy, Zahraa R

doi:10.32604/biocell.2018.07009

Cited by 15 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As one of the conditions that can encourage lipid peroxidation diabetes is one of the pathologic conditions that might indirectly cause liver damage (El-Emshaty et al, 2018). In agreement with Al-Rawi (2007a) and Ene et al's (2007) studies, our present results revealed significant lowering in ALT and AST activities and a significant increase in blood albumin in diabetic animals administered with CQC when compared to the control untreated diabetic group.…”

Section: Discussionsupporting

confidence: 92%

Antidiabetic activity of cobalt–quercetin complex: A new potential candidate for diabetes treatment

Mohamed¹,

Saad²,

Kholoud³

2020

J Appl Pharm Sci

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Antidiabetic activity of cobalt–quercetin complex: A new potential candidate for diabetes treatment

Mohamed¹,

Saad²,

Kholoud³

2020

J Appl Pharm Sci

View full text Add to dashboard Cite

“…The risk model-based screening strategy showed superior net benefit than screening all cirrhotic patients or screening none of the non-cirrhotics. There is an intensive effort to validate sensitive and specific HCC blood-based biomarkers[48,49]. Potentially, these markers may be efficient in early HCC detection and may stratify patients according to their HCC risk.…”

Section: Post-svr Hcc Surveillancementioning

confidence: 99%

Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?

Meringer¹,

Shibolet²,

Deutsch³

2019

WJG

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common and deadly malignancy. The disease usually develops on a background of chronic liver disease. Until recently, the most common etiology was infection with the hepatitis C virus (HCV). The advent of direct-acting antiviral (DAA) therapies has been a major breakthrough in HCV treatment. Sustained virologic response can now be achieved in almost all treated patients, even in patients with a high risk for the development of HCC, such as the elderly or those with significant fibrosis. Early reports raised concerns of a high risk for HCC occurrence after DAA therapy both in patients with previous resection of tumors and those without previous tumors. As the World Health Organization’s goals for eradication of HCV are being endorsed worldwide, the elimination of HCV seems feasible. Simultaneous to the decrease in the burden of cirrhosis from HCV, non-alcoholic fatty liver disease (NAFLD) incidence has been increasing dramatically including significant increased incidence of cirrhosis and HCC in these patients. Surprisingly, a substantial proportion of patients with NAFLD were shown to develop HCC even in the absence of cirrhosis. Furthermore, HCC treatment and potential complications are known to be influenced by liver steatosis. These changes in etiology and epidemiology of HCC suggest the beginning of a new era: The post–HCV era. Changes may eventually undermine current practices of early detection, surveillance and management of HCC. We focused on the risk of HCC occurrence and recurrence in the post–HCV era, the surveillance needed after DAA therapy and current studies in HCC patients with NAFLD.

show abstract

“…Globally, endometrial cancer is the 6th utmost common cancer in females and the utmost common malignancy of the female genital area [25]. Predictive, diagnostic, and prognostic biomarkers were identified for several other cancers [26][27][28]. The present study was the A vital mechanism involved in tumorigenesis is the inhibition of apoptosis [29].…”

Section: Discussionmentioning

confidence: 60%

Livin/BIRC7 gene expression as a possible diagnostic biomarker for endometrial hyperplasia and carcinoma

Elmekkawy

Shoaib

Seleem

et al. 2021

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

Background Livin/BIRC7 is a member of the inhibitors of apoptosis proteins family which are implicated in development of cancer through the inhibition of apoptosis process. This case-control study was intended to investigate livin/BIRC7 gene expression in endometrial hyperplasia and carcinoma and its correlation to some oxidative stress markers in addition to its possible diagnostic performance. Methods This study included 90 participants [30 endometrial hyperplasia patients, 30 endometrial carcinoma patients, and 30 healthy controls]. Livin/BIRC7 gene expression was analyzed using quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Serum catalase activity was assessed by enzyme-linked immunosorbent assay (ELISA) and malondialdehyde level was measured by the colorimetric method. Results Livin/BIRC7 gene expression was significantly (p < 0.001) higher in endometrial carcinoma from patients with endometrial hyperplasia when compared to controls. A positive correlation was found between livin/BIRC7 expression and serum catalase activity and malondialdehyde level in endometrial hyperplasia and carcinoma. The detection of livin/BIRC7 in endometrial carcinoma has excellent sensitivity and specificity. Conclusions Livin/BIRC7 was overexpressed in endometrial carcinoma with excellent power to differentiate endometrial carcinoma from endometrial hyperplasia or healthy subjects, suggesting that it might be a useful molecular marker for endometrial carcinoma diagnosis.

show abstract

Associations between CD133, CK19 and G2/M in cirrhotic HCV (genotype-4) patients with or without accompanying tumor

Cited by 15 publications

References 26 publications

Antidiabetic activity of cobalt–quercetin complex: A new potential candidate for diabetes treatment

Antidiabetic activity of cobalt–quercetin complex: A new potential candidate for diabetes treatment

Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?

Livin/BIRC7 gene expression as a possible diagnostic biomarker for endometrial hyperplasia and carcinoma

Contact Info

Product

Resources

About